Cargando…
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Eribulin mesylate, a synthetic derivative of the anti-mitotic agent halichondrin B, has a unique tubulin-based mechanism of action that is distinct from other anti-microtubule agents including taxanes and vinca alkaloids. Consistent with this unique activity, eribulin has shown clinical efficacy in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917473/ https://www.ncbi.nlm.nih.gov/pubmed/33658845 http://dx.doi.org/10.2147/BCTT.S231298 |